1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...

More documents

Recommendations

Info

46. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P. Psychopharmacol Bull 2008;41(3). 47. Ehrenberg A. La fatigue d´etre soi. Dépression et société. Éditions Odile Jacob, 1998,2000 In Danish 2010 Informations forlag. Copenhagen. 48. Gary Greenberg. Manufactoring depression. The secret history of a modern disease. 2010. Simon and Schuster New York. 49. Abraham J. Pharmaceuticalisation of society in context. Theoretical, empirical and health dimensions. Sociology 2010;44:603-22. 50. American Psychiatric Association. The DSM-IV sourcebook. Volume 1. Washington DC: American Psychiatric Association;1994. 51. Haddad P. Antidepressant discontinuation syndromes. Drug Saf 2001;24:183-97. 52. Minutes from meeting of the Committee on Safety of Medicines held on Thursday 26 March 1998. Date of Summary April 2001. 53. Judge R, Parry MG, Quail D, Jacobson JG. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int clin Psychopharamcol 2002;17:217- 25. 54. Haddad PM, Anderson IM. Recognising and managing antidepressant discontinuation symptoms. Advances In psychiatric Treatment 2007;13:447-57. 55. Haddad P. Do antidepressants have any potential to cause addiction J Psychopharmacol 1999;13(3):300-7. 56. Kramer, J. C., Klein, D. F., Fink, M.: Withdrawal symptoms following discontinuation of imipramine therapy. Am. J. Psychiatr 1961;118:548–50. 57. Oswald I, Lewis SA, Dunleavy DLF, Brezinova V, BriggsM. Drugs of dependence though not of abuse: Flenfluramine and Imipramine. BMJ 1971;3:70-3. 58. Caplan PJ. They say you´re crazy. [place unknown]: Da Capo Press; 1995. 59. Prior L.Documents in health research. In I. Bourgeault R. Dingwall, R. De Vries (Eds). Qualitative methods in health research. London: Sage Pubns;2010. 60. House of Commons. The Influence of the pharmaceutical industry, Health Select Committee Fourth Report of Session 2004-05.Vol 1. 61. 2004 CSM Expert Working Group 62. WHO Techical Report series no 915. WHO Expert Committee on Drug Dependence. Thirty third report. WHO Geneve 2003. 50
63. Abraham J, Davis C. Risking public safety: Experts, the medical profession and acceptable drug injury. Health Risk and Society 2005;7:379-95. 64. McGoey L. On the will to ignorance in bureaucracy. Economy and Society 2007;36:212-35. 65. Healy D. Did regulators fail over selective serotonin reuptake inhibitors BMJ 2006;333: 92-95. 66. Abraham J (2003a). The science and politics of Medicines control. Drug Safety, 26 (3),135- 43. 67. Abraham J (2003b). Learning from drug disasters and reforming medicines regulation. Critical Public Health, 13 (3), 269-79. 68. Abraham J. Deficits, expectations and paradigms in British and American Drug safety assessments: prosing open the black box of regulatory science. Sci Technol human values 2007;32:399-431. 51
Page 1 and 2: Selective serotonin reuptake inhibi
Page 3 and 4: 1. Preface and acknowledgement 1.1
Page 5 and 6: 2. Abstract Psychotropic drug use h
Page 7 and 8: 3. Danish summary Brugen af psykotr
Page 9 and 10: 4. Introduction Psychotropic medici
Page 11 and 12: It is pretty clear that the inclusi
Page 13 and 14: The first two studies led to the th
Page 15 and 16: 4.1. List of abbreviations ATC CPMP
Page 17 and 18: to accept withdrawal reactions as a
Page 19 and 20: than in the former DSM-III were des
Page 21 and 22: 5. Objectives In the light of this
Page 23 and 24: including gifts, drug samples and i
Page 25 and 26: The data in the register represent
Page 27 and 28: DDD/1000 inhabitants/day Figure 1:
Page 29 and 30: general, a motivated GP in an urban
Page 31 and 32: of Diseases (ICD) is organized by t
Page 33 and 34: palpitations skin rash, itching abd
Page 35 and 36: which withdrawal reaction is one cr
Page 37 and 38: It was not possible to use a system
Page 39 and 40: http://www.mhra.gov.uk/home/groups/
Page 41 and 42: 21876/Seroxat%2C+filmovertrukne+tab
Page 43 and 44: Abraham and Davis have explored dru
Page 45 and 46: 8. Perspectives Patient safety is a
Page 47 and 48: 9. References 1. Hansen EH, Gyldmar
Page 49: 33. Classifications [Internet]. WHO
Page 53 and 54: International Journal of Risk & Saf
Page 55 and 56: M. Nielsen and P. Gøtzsche / An an
Page 61 and 62: s_bs_banner REVIEW doi:10.1111/j.13
Page 63 and 64: 902 Margrethe Nielsen et al. RESULT
Page 65 and 66: 904 Margrethe Nielsen et al. Table
Page 67 and 68: 906 Margrethe Nielsen et al. abrupt
Page 69 and 70: 908 Margrethe Nielsen et al. 40. Sc
Page 71 and 72: Abstract Aim: Our objective was to
Page 73 and 74: There are different views whether S
Page 75 and 76: Results We identified 6 documents r
Page 77 and 78: In 1998, it was stated that SSRIs d
Page 79 and 80: having both medical and abuse poten
Page 81 and 82: for documents that were available o
Page 83 and 84: 16. Nielsen M, Hansen EH and Gøtzs
Page 85 and 86: Table 1: Search strategy Source Sea
Page 87 and 88: 1988 Medicines Control Agency, Comm
Page 89 and 90: 2000 Medicines Control Agency, Comm
Page 91 and 92: 2003 Meeting 16 September CSM and E

1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?

1 Selective serotonin reuptake inhibitors (SSRI) â sales, withdrawal ...